==== Front Cureus Cureus 2168-8184 Cureus 2168-8184 Cureus Palo Alto (CA) 10.7759/cureus.11307 Gastroenterology Oncology Metastasis to Breast From Carcinoma Gallbladder: A Case Report and Review of Literature Muacevic Alexander Adler John R Sahoo Bijayalaxmi Sr.1 Barik Sandip 1 Mishra Pritinanda 2 Das Majumdar Saroj Kumar 1 Parida Dillip Kumar 1 1 Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, IND 2 Pathology, All India Institute of Medical Sciences, Bhubaneswar, IND Sandip Barik sandip.barik1@gmail.com 3 11 2020 11 2020 12 11 e113073 11 2020 Copyright © 2020, Sahoo et al.2020Sahoo et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.This article is available from https://www.cureus.com/articles/42381-metastasis-to-breast-from-carcinoma-gallbladder-a-case-report-and-review-of-literatureGallbladder cancer (GBC) is the commonest malignancy among biliary tract cancers. Locoregional spread in GBC is more common than distant metastasis. The liver and abdominal lymph nodes is the most common site of distant metastasis. Breast metastasis is a rare site of dissemination. GBC is an aggressive tumor and carries a poor prognosis, with a five-year survival rate of less than 10%. Metastasis to the breast from a gallbladder is significantly less and accounts for very few cases. Here, we are reporting a rare case of carcinoma gallbladder metastasis to the breast who survived for 38 months from the diagnosis of GBC and around 25 months after breast metastasis. breast metastasisgall bladder canceruncommon sitemetastatic gall bladderchemotherapysurvivalThe content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus. ==== Body Introduction Gallbladder cancer (GBC) is the most common malignancy of the biliary tract, representing 80%-95% of biliary tract cancers worldwide. It is the sixth most common cancer among gastrointestinal (GI) cancer [1]. It accounts for only 2% to 4% of all malignant GI tumors [2-3]. Cholelithiasis and chronic cholecystitis are the most common predisposing factors associated with GBC. Women in the seventh decade are affected three to four times more often than men [4]. Locoregional spread in GBC is more common than distant metastasis. Distant metastases usually occur in the liver, lymph nodes, and peritoneum [5]. GBC is an aggressive tumor and carries a poor prognosis with a five-year survival rate of less than 10% (1). GBC metastasis to the breast is very rare. To date, as per our knowledge, only three cases have been reported [6].  We report a case of carcinoma gallbladder with breast metastasis and a short review of the literature. Case presentation A 55-year-old female, known case of hypothyroidism, on medication for five years, presented with complaints of a painless lump over an old abdominal scar for one month. The patient had undergone laparoscopic cholecystectomy in 2015 for chronic cholelithiasis. The histopathological study of the operated specimen was suggestive of biliary intraepithelial neoplasm. On examination, a 2.5 x 2 cm, hard, non-tender nodule was palpable over the cholecystectomy scar. Fine needle aspiration cytology (FNAC) was advised from the scar nodule, which showed metastatic adenocarcinoma. A contrast-enhanced computed tomography (CT) scan showed a solid mass lesion of size 3x2 cm in the parietal wall of the anterior abdominal in the epigastric region on the right side, with infiltration to the right rectus sheath and muscle, along with enlarged periportal and para-aortic lymph nodes. Her CA 19.9 level was elevated (3.73 ng/ml). She was started on gemcitabine (1 gm/m2) and oxaliplatin (100 mg/m2) based chemotherapy. She defaulted treatment after completing three cycles of chemotherapy. Contrast-enhanced computed tomography (CECT) abdomen done five months after the discontinuation of treatment showed an increase in lesion size for which she underwent wide local excision of the abdominal wall nodule. The histopathology report showed metastatic adenocarcinoma with a tumor size of 6 x 5 x 4 cm. She was continued gemcitabine (1 gm/m2) and oxaliplatin (100 mg/m2) chemotherapy for three more cycles. After completing three cycles of chemotherapy, she was on regular follow-up. After one year of completing chemotherapy, the patient developed a right side breast lump. On examination, a hard, non-tender lump of size 3 x 1.5 cm palpable over the upper outer quadrant (UOQ) of the right breast with no axillary lymphadenopathy (Figure 1). Figure 1 Hard lump sized 3 x 1.5 cm over the UOQ of the right breast UOQ: upper outer quadrant The positron emission tomography-computed tomography (PET-CT) scan showed increased uptake of fluorodeoxyglucose (FDG) in the gallbladder fossa and UOQ of the right breast of size 1.9 x 1.7 cm, with a standardized uptake value (SUV) of 3.7 (Figure 2). Figure 2 Whole-body PET-CT scan showing increased FDG uptake in the UOQ of the right breast of size 1.9 x 2.7 cm, SUVmax = 3.7 PET-CT: positron emission tomography-computed tomography; FDG: fluorodeoxyglucose; UOQ: upper outer quadrant; SUVmax: maximum standard unit value Excisional biopsy of the breast lump showed metastatic adenocarcinoma with CK-7 and CK-20 strongly positive. CDX-2, GATA-3, mammaglobulin, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) was negative, compatible with the primary biliary origin (Figures 3-4). Figure 3 10x H&E microscope feature Showing the cells have elongated nuclei and supra-nuclear clearing, so metastatic adenocarcinoma possibly from gallbladder primary H&E: hematoxylin and eosin Figure 4 2x H&E microscope view from the breast lump Showing linear cores of fibrocollagenous tissue with malignant epithelial cells in a glandular pattern Palliative chemotherapy with nab-paclitaxel and gemcitabine was advised for three cycles. Interim evaluation with PET-CT scan showed disease progression (Figure 5). Figure 5 Whole-body PET-CT scan showing disease progression both in gallbladder fossa (size 4.9 x 6.3 x 6.1 cm, SUVmax = 9.86 and breast lump (size 6 x 4.6 cm, SUVmax = 3.37) compared to previous PET-CT scan PET-CT: positron emission tomography-computed tomography; SUVmax: maximum standard unit value Due to disease progression, the chemotherapy regimen was changed to nab-paclitaxel and carboplatin, but after taking two cycles of chemotherapy, she succumbed to the metastatic disease. Discussion Gallbladder cancer (GBC) is the most common malignancy of the biliary tract, representing 80%-95% of biliary tract cancers worldwide. It is the sixth most common cancer among gastrointestinal cancers [1]. Although the etiology of the carcinoma of the gallbladder is obscure, cholelithiasis and chronic cholecystitis are the most frequent cause. GBC is three- to four-fold more prevalent among women than men, usually in the seventh decade of life [4]. GBC is aggressive cancer and has a poor prognosis. Five-year survival is only less than 10% [7-8]. Locoregional spread in GBC is more common than distant metastasis. The leading modes of dissemination in GBC are lymphatic, vascular, neural, intraperitoneal, and intraductal [9]. The common site of distant metastasis are the liver, abdominal lymph nodes, and peritoneum and rarely to the bowel, cervix, kidney, thyroid, and heart [10-11]. The lung is the most common site of extra-abdominal metastasis [12-13]. The incidence of breast metastasis from other primary sites accounts for only 0.5%-0.6% [14]. Breast metastasis is mostly seen from hematological malignancy, melanoma, and small cell carcinoma of the lung [15]. Metastasis to the breast from the gallbladder is significantly less and account for very few cases [6-16]. The hematogenous route is the most common mode of spread to the breast. Unlike primary breast malignancy, metastasis to the breast from other primaries are usually firm, well-circumscribed, and uninvolved skin. Mammography shows a lack of microcalcification. The upper outer quadrant is the most common location for involvement, mostly 62% [17]. Due to the rarity of the case, no definite consensus is there for proper diagnosis and management. Few studies show an average survival of 10-12 months, and with no intervention, survival is less than a month [18]. Gemcitabine-based chemotherapy is the most commonly used regimen. Aggressive management with systemic chemotherapy and surgery and radiation may extend overall survival to a few months. In our case, the patient underwent wide local excision of port site recurrence followed by two lines of palliative chemotherapy with gemcitabine with oxaliplatin and nab-paclitaxel with gemcitabine. Due to this aggressive multimodality treatment modality, our patient survived for 38 months from the diagnosis and around 25 months after breast metastasis. Conclusions The incidence of breast metastasis in carcinoma gallbladder is scarce and a rare finding. Despite treating aggressively with chemotherapy, overall survival for these patients is inferior. We should consider multimodality treatment to improve survival. The authors have declared that no competing interests exist. Human Ethics Consent was obtained by all participants in this study ==== Refs References 1 Epidemiology and molecular pathology of gallbladder cancer CA Cancer J Clin Lazcano-Ponce EC Miquel JF Muñoz N 349 364 51 2001 11760569 2 Gallbladder cancer: epidemiology and outcome Clin Epidemiol Hundal R Shaffer EA 99 109 6 2014 24634588 3 Gallbladder cancer in the twentieth century: single institution's experience World J Surg Grobmyer SR Lieberman MD Daly JM 47 49 28 2004 14639492 4 Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience Arch Surg Konstantinidis IT Deshpande V Genevay M 441 447 144 2009 19451486 5 Primary carcinoma of the gallbladder Surg Gynecol Obstet Piehler JM Crichlow RW 929 942 147 1978 https://pubmed.ncbi.nlm.nih.gov/362580/ 362580 6 A rare case of gallbladder carcinoma metastases to the breast treated with curative intent Trop Gastroenterol Kallianpur AA Shukla NK Deo SV Singh M Subi TS Kapali A 155 158 33 2012 23025069 7 Gallbladder cancer worldwide: geographical distribution and risk factors Int J Cancer Randi G Franceschi S La Vecchia C 1591 1602 118 2006 https://pubmed.ncbi.nlm.nih.gov/16397865/ 16397865 8 Epidemiology and molecular pathology of gallbladder cancer CA Cancer J Clin Lazcano-Ponce EC Miquel JF Muñoz N 349 364 51 2001 11760569 9 Gall bladder carcinoma: aggressive malignancy with protean locoregional and distant spread World J Clin Cases Dwivedi AN Jain S Dixit R 231 244 3 2015 25789296 10 Diet and gallbladder cancer: a case-control study Eur J Cancer Prev Pandey M Shukla VK 365 368 11 2002 12195163 11 Vertebral metastasis in gallbladder carcinoma- an unusual site Int J Med Rev Case Rep Gupta N Goswami B Mahajan N Dey S 165756 2012 2012 https://ibimapublishing.com/articles/IJCRM/2012/165756/ 12 Breast metastasis from carcinoma of gall bladder Int J Health Allied Sci Malik AA Wani ML Wani SN Malik RA Malik TR 35 36 2 2013 13 Gallbladder carcinoma Eur J Surg Oncol Miller G Jarnagin WR 306 312 34 2008 17964753 14 Bile peritonitis secondary to breast cancer metastatic to the gallbladder Am J Gastroenterol Shah RJ Koehler A Long JD 1379 1381 95 2000 10811372 15 Metastases to the breast: differential diagnosis from primary breast carcinoma J Surg Oncol Vergier B Trojani M de Mascarel I Coindre JM Le Treut A 112 116 48 1991 1921396 16 Metastatic breast carcinoma of the gallbladder J Surg Oncol Beaver BL Denning DA Minton JP 240 242 31 1986 3724179 17 Gynecologic cancers metastatic to the breast J Am Coll Surg Moore D Wilson DK Hurteau J Look KY Stehman FB Sutton G 178 181 187 1998 http://17. Moore D, Wilson DK, Hurteau J, Look KY, Stehman FB, Sutton GP. Gynecologic cancers metastatic to the breast. J Am Coll Surg 1998;187:178-81 9704965 18 Gallbladder cancer and trocar site recurrences Am J Surg Ricardo AE Feig BW Ellis LM Hunt KK Curley SA MacFadyen BV Mansfield PF 619 622 164 1997